遊雅堂入金ボーナス

Corporate Corporate Basic Information Message from the President Corporate Profile / Access ∟Mitsubishi Chemical Group Corporation ∟Mitsubishi Chemical Corporation ∟Mitsubishi Tanabe Pharma Corporation ∟Nippon Sanso Holdings Corporation Leadership Organization Chart Global Network Number of Subsidiaries History Corporate Brochure Evaluation by Outside Parties Approach to Corporate Activities Group Concept Charter of Corporate Behavior Value Creation Model Health and Productivity Management Management Strategy Management Policy Business Strategy ∟Specialty Materials ∟Industrial Gases ∟Health Care ∟MMA ∟Petrochemicals and Carbon Products Governance Corporate Governance ∟Corporate Governance Guidelines Risk Management Compliance Media KAITEKI Solution Center  Digital Showroom  Social Media ∟LinkedIn account  ∟X account  ∟YouTube channel  Products Innovation Innovation CTO Message --> Innovation Strategy Intellectual Property Strategy Mitsubishi Chemical Corporation R&D Main R&D Organization Award History Paper Submission Investors Investors Management Policy Message from the President --> Management Policy Disclosure Policy IR News IR News TSE Filings Basic Information Chart IR Calendar Financial Data ∟Financial Highlight ∟Historical DATA  Evaluation by Outside Parties (ESG) Other IR Information ∟FAQ on IR ∟Contact on IR ∟IR Sitemap IR library Financial Results Operating Summaries Analysts Meeting Materials Integrated Reports Securities Reports Report in Line with the Recommendations of the TCFD To Our Individual Investors The Mitsubishi Chemical Group in Numbers Stock and Bond Information ∟Stock Information ∟Dividend ∟Shareholders Meeting ∟Articles of Incorporation ∟Ratings and Bonds Sustainability Sustainability Sustainability Activities Sustainability Approach and Promotion Structure Material Issues and　Sustainability(MOS) Indices​ ESG Initiatives Environment Social Governance Sustainability Data Sustainability (MOS) Results Non-Financial Data Sheets GRI Standards Integrated report "KAITEKI Report" News News Releases Information IR News TSE Filings Contact Us 日本語 English 中文 --> --> --> --> HOME Corporate Information Strategy Health Care Health Care From KAITEKI Report 2023 issued in September 2023 Strengthening the pipeline and maximizing product value New treatment option for ALS patients Strengthening the pipeline and maximizing product value To achieve our fiscal 2025 targets, we are focusing on (1) maximizing the value of priority products in Japan and the United States and (2) strengthening partnering and establishing new sales and development alliances. We restructured our business in fiscal 2022, including withdrawal from the business operated by Medicago Inc. that was developing a vaccine against COVID-19. We will now focus R&D spending on indications in the core areas of central nervous system, immuno-inflammation, and oncology, with the goal of strengthening our pipeline and maximizing product value. Strategic focus Advance precision medicine through upgraded R&D processes Focus innovation development on rare diseases and continue to invest in a new pipeline Leverage partnerships for development and sales Change in EBITDA SWOT analysis Strengths New drug creation capabilities in the pharmaceuticals business Strong presence in priority drug markets including central nervous system, immuno-inflammation, and diabetes and kidney Weaknesses Delayed expansion into global markets Opportunities Demand for provision of diverse healthcare solutions Increasingly diverse drug discovery activities due to technological advances Unmet medical needs Threats Declining probability of success with drug discovery Increasing R&D expenditures Government measures to control healthcare expenditures, generic drugs entering the market New treatment option for ALS patients The oral suspension formulation of edaravone was approved as a treatment for amyotrophic lateral sclerosis (ALS) in the United States in May 2022, in Canada in November, in Japan in December, and in Switzerland in May 2023. This oral suspension formulation of edaravone contains the same active ingredient as the intravenous infusion formulation RADICUT (U.S. product name: RADICAVA). We undertook its development with the aim of reducing burdens on ALS patients such as injection pain and outpatient visits. Previously, intravenous infusion was the only available route of administration, but now there is a new treatment option. Launched Global (FY of U.S. launch) Japan, China Area Focus Targeted indications Key markets MCG Group’s key growth products Launch plans for main pipeline programs FY2022 FY2023 FY2024 From FY2025 Central nervous system Development, sales ALS, Tardive dyskinesia U.S., Japan RADICAVA DYSVAL MT-1186 ALS (oral suspension) (U.S., Canada) MT-5199 Tardive dyskinesia (Japan) MT-1186 ALS (oral suspension) (Japan)*2 ND0612 Parkinson’s disease (global) MT-0551 Myasthenia gravis (Japan) Immuno-inflammation Development, sales Inflammatory bowel disease, Erythropoietic protoporphyria U.S., Japan STELARAMT-7117       MT-0551 IgG4-related disease (Japan) MT-7117 Erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP) (global) Diabetes and kidney Sales Type 2 diabetes, Chronic kidney disease (CKD) associated with type 2 diabetes Japan MOUNJARO CANAGLU TA-7284 CKD associated with type 2 diabetes*1 (Japan) MP-513 Type 2 diabetes (China)   TA-7284 OD tablets Type 2 diabetes, CKD associated with type 2 diabetes*1 (Japan)   Oncology Development Rare cancers U.S., Japan MT-2111       MT-2111 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (Japan) *1CKD associated with type 2 diabetes, but excludes patients with end-stage renal failure or undergoing dialysis *2Approved in Switzerland Corporate Information Corporate Information Corporate Information Basic Information Message from the President Corporate Profile / Access ∟Mitsubishi Chemical Group Corporation ∟Mitsubishi Chemical Corporation ∟Mitsubishi Tanabe Pharma Corporation ∟Nippon Sanso Holdings Corporation Leadership Organization Chart Global Network Number of Subsidiaries History Corporate Brochure Evaluation by Outside Parties Approach to Corporate Activities Group Concept Charter of Corporate Behavior Value Creation Model Health and Productivity Management Management Strategy Management Policy Business Strategy ∟Specialty Materials ∟Industrial Gases ∟Health Care ∟MMA ∟Petrochemicals and Carbon Products Governance Corporate Governance ∟Corporate Governance Guidelines Risk Management Compliance Media KAITEKI Solution Center Digital Showroom Social Media ∟LinkedIn account  ∟X account  ∟YouTube channel  Business・Products Business・Products Innovation Innovation Innovation CTO Message --> Innovation Strategy Intellectual Property Strategy Mitsubishi Chemical Corporation R&D Main R&D Organization Award History Paper Submission Investor Relations Investor Relations Investor Relations Management Policy Message from the President --> Message from the CFO --> Outside Directors’ Discussion Meeting --> Management Policy Disclosure Policy IR News IR News TSE Filings Basic Information Chart IR Calendar Financial Data Evaluation by Outside Parties (ESG) Other IR Information ∟FAQ on IR ∟Contact on IR ∟IR Sitemap IR library Financial Results Operating Summaries Analysts Meeting Materials Integrated Reports Securities Reports Report in Line with the Recommendations of the TCFD To Our Individual Investors The Mitsubishi Chemical Group in Numbers Stock and Bond Information Sustainability Sustainability Sustainability Sustainability Activities Sustainability approach and promotion structure Material Issues and Sustainability(MOS) Indices ESG Initiatives Environment Society Governance Sustainability Data Sustainability (MOS) results Non-Financial Data Sheets GRI Standards KAITEKI Solution Center News Releases Information Digital Showroom Contact Us FAQ The Mitsubishi Chemical Group Official Accounts Sitemap Terms of Use Privacy Policy Social Media Terms of Use Copyright © Mitsubishi Chemical Group Corporation.